The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C

Liver International

Volumn 29, Issue 5, 2009, Pages 748-753

  Corey, Kathleen E ^a   Shah, Nirali ^a   Misdraji, Joseph ^a   Abu Dayyeh, Barham K ^a   Zheng, Hui ^a   Bhan, Atul K ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ACE inhibitors; Angiotensin II receptor blocking agents; Cirrhosis; Diabetes; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; QUINAPRIL; TRANDOLAPRIL; VALSARTAN; VASODILATOR AGENT;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DRUG USE; FEMALE; GENDER; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEPATITIS C; HUMANS; HYPERTENSION; LIVER CIRRHOSIS; MALE; MASSACHUSETTS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 64749115204     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.01973.x     Document Type: Article

References (33)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075-80.
3. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-704.
4. Fartoux L, Poujol-Robert A, Guechot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
5. Bataller R, Gabele E, Parsons CJ, et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005; 41: 1046-55.
6. Wei YH, Jun L, Qiang CJ. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl 4 in rats. Dig Dis Sci 2004; 49: 1589-94.
7. Tuncer I, Ozbek H, Ugras S, Bayram I. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp Toxicol Pathol 2003; 55: 159-66.
8. Tox U, Steffen HM. Impact of inhibitors of the renin-angiotensin-aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem 2006; 13: 3649-61.
9. Yoshiji H, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. J Gastroenterol Hepatol 2007; 22 (Suppl. 1): S93-5.
10. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-51.
11. Paizis G, Gilbert RE, Cooper ME, et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001; 35: 376-85.
12. Jonsson JR, Clouston AD, Ando Y, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148-55.
13. Croquet V, Moal F, Veal N, et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 2002; 37: 773-80.
14. Xu W, Song S, Huang Y, Gong Z. Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats. J Gastroenterol Hepatol 2006; 21: 1250-6.
15. Yoshiji H, Fukui H. Renin-angiotensin system and progression of chronic liver diseases. J Gastroenterol 2006; 41: 1020-2.
16. 4. Biochem Biophys Res Commun 2003; 308: 177-83.
17. Yoshiji H, Noguchi R, Fukui H. Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 215-6.
18. Yoshiji H, Noguchi R, Kojima H, et al. Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. World J Gastroenterol 2006; 12: 6786-91.
19. Terui Y, Saito T, Watanabe H, et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002; 36 (Part 1): 1022.
20. Colmenero J, BR, Forns X, et al. Long-term treatment with losartan reduces the inflammatory activity and the expression of key genes involved in liver fibrogenesis in patients with chronic hepatitis C. J Hepatol 2007; 46 (Suppl. S1): 107.
21. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-5.
22. Debernardi-Venon W, Martini S, Biasi F, et al. AT1 receptor antagonist candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026-33.
23. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
24. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
25. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-52.
26. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-15.
27. Sookoian S, Fernandez MA, Castano G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study. World J Gastroenterol 2005; 11: 7560-3.
28. Rimola A, Londono MC, Guevara G, et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004; 78: 686-91.
29. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-62.
30. Shiffman ML. Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. Curr Gastroenterol Rep 2006; 8: 46-52.
31. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
32. Yoshiji H, Kuriyama S, Noguchi R, et al. Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development. Liver Int 2005; 25: 153-61.
33. DiBisceglie A, Shiffman ML, Everson G, et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C. Hepatology 2007; 4 (Suppl. 1): 233A, abstracts.